KOL Identification

A major diagnostics manufacturer had developed a novel technology for the rapid detection of infectious pathogens and required assistance in developing commercialization strategy and sales tactics. DeciBio’s services were contracted to profile relevant stakeholders, characterize existing workflows and acquisition / implementation processes, and develop a product-specific launch strategy.

A multi-billion dollar life science company needed pre diligence on a potential acquisition target

A group asked DeciBio to identify and evaluate clinical genetic testing labs for potential acquisition

A large multi-national diagnostic company was interested in understanding the market landscape and potential strategy for the decentralization of NIPT in the U.S.

A top-10 scientific service provider wanted to quantify the size of the CGT services market and understand trends within

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings